New drug aims to sharpen thinking in Huntington's patients
NCT ID NCT05358821
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested whether SAGE-718, an experimental oral drug, can improve cognitive function in people with early Huntington's disease. 69 participants took either the drug or a placebo for 28 days. The main goal was to measure changes in thinking skills using a battery of cognitive tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SAGE-718 (oral capsules)
What this could lead to
If successful, this could point toward a treatment to improve thinking and daily functioning in people with early Huntington's disease.
What could go wrong
This is a small, early-phase trial (Phase 2) with only 69 participants. The drug may not show meaningful benefits over placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sage Investigational Site
Birmingham, Alabama, 35233, United States
-
Sage Investigational Site
Los Alamitos, California, 90720, United States
-
Sage Investigational Site
Englewood, Colorado, 80113, United States
-
Sage Investigational Site
Washington D.C., District of Columbia, 20057, United States
-
Sage Investigational Site
Boca Raton, Florida, 33431, United States
-
Sage Investigational Site
Tampa, Florida, 33602, United States
-
Sage Investigational Site
Chicago, Illinois, 60612, United States
-
Sage Investigational Site
Baltimore, Maryland, 21218, United States
-
Sage Investigational Site
New York, New York, 10027, United States
-
Sage Investigational Site
Chapel Hill, North Carolina, 27599, United States
-
Sage Investigational Site
Cincinnati, Ohio, 45221, United States
-
Sage Investigational Site
Philadelphia, Pennsylvania, 19104, United States
-
Sage Investigational Site
Houston, Texas, 77030, United States
-
Sage Investigational Site
Montreal, H2X 3E4, Canada